Transgene SA
11 rue de MOLSHEIM, 67082
Strasbourg
Cedex
France
Tel: 011-33-3-88-27-91-21
Fax: 011-33-3-88-27-91-11
Website: http://www.transgene.fr/
327 articles about Transgene SA
-
Transgene and BioInvent Present Preclinical Data Highlighting the Robust Anti-Tumoral Activity of BT-001 Oncolytic Virus at SITC 2021
11/9/2021
Transgene and BioInvent Present Preclinical Data Highlighting the Robust Anti-Tumoral Activity of BT-001 Oncolytic Virus at SITC 2021
-
Transgene Reports Business Update and Q3 2021 Financial Position
11/4/2021
Transgene today announces its business update for the quarter ending September 30, 2021.
-
BioInvent and Transgene to present preclinical data on BT-001 oncolytic virus at SITC 2021
10/1/2021
BioInvent International AB and Transgene announce that they will present additional preclinical data on their novel dual mechanism-of-action oncolytic Vaccinia virus BT-001 at the 36th Annual Meeting of the Society for Immunotherapy of Cancer in November 2021.
-
Transgene’s Two Innovative Platforms Progressing Well - Financial Visibility Extended Until End 2023
9/22/2021
Transgene publishes its financial results for the six-month period ended June 30, 2021, and provides an update on the progress of its portfolio of clinical-stage drug candidates.
-
Clinical Catch-Up: September 13-17
9/20/2021
With a conference the size of ESMO, it’s impossible to cover all the exciting news, but here are many of the highlights. Here’s a look. -
Transgene Presents Data From Phase I Clinical Trial Confirming the Potential of the Oncolytic Virus TG6002
9/16/2021
Transgene announces the presentation of data from a Phase I study combining intravenous oncolytic virus TG6002 and oral 5-FC in patients with advanced gastrointestinal carcinomas at the European Society for Medical Oncology virtual meeting taking place from September 16-21, 2021.
-
Transgene Announces Upcoming Investor Meetings - Sep 13, 2021
9/13/2021
Transgene, a biotech company that designs and develops virus-based immunotherapeutics against cancer, announces that Management will participate in the upcoming investor events.
-
Transgene Participates in New Cancer Research Consortium
9/1/2021
Transgene announces its participation in the launch of PERSIST-SEQ, a new international consortium of academic and industrial leaders in the field of cancer research.
-
First Head & Neck Cancer Patient Enrolled in the UK in a Phase I Trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy
6/28/2021
Transgene, a biotech company that designs and develops virus-based immunotherapeutics against cancer, announces that the first UK patient has been enrolled in the Phase I clinical trial of TG4050, Transgene’s innovative individualized cancer immunotherapy, currently being evaluated in HPV-negative head and neck cancer patients.
-
BioInvent and Transgene receive IND approval from the U.S. FDA for BT-001, a novel oncolytic virus for the treatment of solid tumors
5/27/2021
BioInvent International AB and Transgene announce that their Investigational New Drug application for BT-001 has been granted by the U.S. Food and Drug Administration.
-
Transgene and BioInvent Receive IND Approval from the U.S. FDA for BT-001, a Novel Oncolytic Virus for the Treatment of Solid Tumors
5/27/2021
Transgene and BioInvent International AB announce that their Investigational New Drug application for BT-001 has been granted by the U.S. Food and Drug Administration.
-
Transgene: Combined General Meeting of May 26, 2021
5/26/2021
The Combined Ordinary and Extraordinary General Meeting of Transgene’s shareholders was held at 10:00 a.m. at the Company's headquarters chaired by Hedi Ben Brahim, Chairman and CEO, to approve the Company’s financial statements for the year ended December 31, 2020 and to vote the other resolutions submitted to their approval.
-
Transgene Reports Business Update and End Q1 2021 Financial Position
4/27/2021
TG4001 - Regulatory clearance received for randomized Phase II trial – First patient expected to be enrolled in 2Q 2021 TG6002 - Initial Phase I data provides clinical proof of concept for the intravenous administration of Transgene’s double deleted VV cop TK-RR- patented virus backbone, the basis of the Invir.IO™ oncolytic virus backbone
-
Transgene Announces Upcoming Investor Meetings - Apr 12, 2021
4/12/2021
Strasbourg, France, April 12, 2021, 05:45 pm CET – Transgene, a biotech company that designs and develops virus-based immunotherapeutics against cancer, announces that Management will participate in the upcoming investor events
-
Clinical Catch-Up: April 5-9
4/12/2021
It was a relatively quiet week for clinical trial announcements, but there were a few standouts. Read on for more. -
Transgene Presents Initial Phase I Data of TG6002, Highlighting the Potential of the Intravenous Administration of Its Oncolytic Viruses
4/9/2021
Intravenous administration could allow oncolytic viruses from Transgene’s Invir.IO™ platform to be used to treat a broad range of solid tumors
-
Transgene: Availability of Preparatory Documents for the Combined General Meeting of May 26, 2021
4/7/2021
Transgene: Availability of Preparatory Documents for the Combined General Meeting of May 26, 2021
-
Clinical Catch-Up: March 8-12
3/15/2021
It was another busy week for clinical trial announcements. Here’s a look including trials for COVID-19, migraine, Parkinson's disease, Alzheimer's, HIV and more. -
Transgene: Significant Milestones Achieved on All Drug Candidates in 2020 and Financial Visibility until 2022
3/10/2021
Transgene: Significant Milestones Achieved on All Drug Candidates in 2020 and Financial Visibility until 2022 TG4050 : first patients treated in two clinical trials of the novel individualized immunotherapy based on the myvac ® technology – First data expected in 4Q 2021 TG4001 : expanded randomized Phase II trial to start in HPV-positive anogenital cancers, based on encouraging Phase Ib/II data
-
Transgene Expands Phase II Clinical Trial of Therapeutic Vaccine TG4001 in Combination With Avelumab Versus Avelumab Monotherapy in Patients With HPV16-positive Anogenital Cancers
3/10/2021
- Enrollment of the first patient is expected in Q2 2021 - Trial will focus on patients without liver metastases, based on encouraging data in Phase Ib/II study - Trial targets indications where clinical outcomes can be improved versus standard therapeutic options and immune checkpoint inhibitors (“ICIs”) - Continued clinical collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to conduct the expanded Phase II study